NCT01911611已完成1 期
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Safety: Incidence of adverse events
研究概览
简要总结
This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics of RO6870868 in healthy volunteers. Subjects will be randomized to receive single ascending doses of either RO6870868 or placebo, with or without food.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects, 18 to 65 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination
- •Women of non-childbearing potential including women who have undergone hysterectomy or bilateral oophorectomy and postmenopausal females
- •Male subjects must be willing to use effective contraception as defined by protocol for the duration of the study and for one month after the last dose of study medication
- •Body Mass Index (BMI) at screening of 18 to 32 kg/m2, inclusive
- •Non-smokers, or use of < 10 cigarettes (or equivalent nicotine-containing product) per day
- •No medical or social conditions that would potentially interfere with the subjects ability to comply with the study visit schedule or the study assessments
排除标准
- •Pregnant (positive pregnancy test) or lactating women, and male partners of women who are pregnant or lactating
- •History of drug or alcohol abuse within the last year
- •History of immunologically mediated disease
- •History or symptoms of any significant disease including (but not limited to) neurological, cardiovascular, endocrine, respiratory, gastrointestinal, hepatic, or renal disorder
- •Personal or family history of congenital long QT syndrome or sudden death
- •Evidence of an active or suspected cancer or a history of malignancy where in the investigator's opinion, there is a risk of recurrence. History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic oral or inhaled corticosteroids) </= 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
- •Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable)
- •History of significant psychiatric disease
- •Significant acute infection, e.g., influenza, local infection, acute gastrointestinal symptoms or any other clinically significant illness within two weeks of dose administration
- •History of gastrointestinal disease including inflammatory bowel disease, peptic ulcer disease, gastrointestinal hemorrhage
- •Inadequate hematologic, renal or liver function
- •Positive for hepatitis A, hepatitis B, hepatitis C, or HIV infection
- •History (within 3 months of screening) of alcohol consumption exceeding 14 units per week on average (1 unit = 10 grams of alcohol). Alcohol consumption will be prohibited at least 48 hours before screening, 48 hours before admission, 48 hours after each dose, and 48 hours before each scheduled visit
- •Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- •Subjects who had received IFN or peginterferon within 8 weeks prior to dosing
- •Participation in other clinical studies of a new chemical entity within 60 days prior to study randomization
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: placebo (Drug)
RO6870868
Experimental
干预措施: RO6870868 (Drug)
结局指标
主要结局
Safety: Incidence of adverse events
时间窗: up to 44 days
次要结局
- Pharmacokinetics: Area under the concentration-time curve (AUC)(Pre-dose and up to 48 hours post-dose)
- Pharmacokinetics: Maximum plasma concentration (Cmax)(Pre-dose and up to 48 hours post-dose)
- Effect of food on pharmacokinetics: Area under the concentration-time curve (AUC)(Pre-dose and up to 48 hours post-dose)
- Pharmacodynamics: Cytokines/neopterin levels(Pre-dose and up to 48 hours post-dose)
研究者
相似试验
终止
1 期
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult SubjectsImmune Complex-mediated Autoimmune DiseasesNCT04446000CSL Behring52
已完成
1 期
A Study of High Dose MHAA4549A in Healthy VolunteersHealthy VolunteerNCT02284607Genentech, Inc.14
终止
1 期
Safety Study of SLV213 for the Treatment of COVID-19.COVID-19NCT06146374National Institute of Allergy and Infectious Diseases (NIAID)16
终止
1 期
Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy SubjectsDiabetesNCT05330208Beijing Suncadia Pharmaceuticals Co., Ltd60
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy SubjectsHealthy VolunteersNCT02934269Celgene40